I agree with you Buckeyes.

Just getting caught up on the great posts. Hope BDAZ and other science/med types chime in on apabetalone’s selectivity.  This is where I learn everything about RVX.

I got a real chuckle out of the following statement in the May 21, 2022 Globe article from All Blue, the company that bid $10.50/share in an attempted takeover of Zymeworks, which was rejected as opportunistic.

• “In the April 28th letter to the board outlining it’s bid , All Blue stated Zymeworks had suffered from “severe value erosion due to a number of serious missteps by an unfocused leadership with no clear strategy for improving performance.” "

Sound familiar? So it appears that our RVX CEO may not be the only biotech CEO perceived as a deadbeat loser as viewed from the eyes of some investors.

Of course Zymeworks replaced the CEO, Ali Tehrani with Mr Galbraith, a biotech financing veteran. So their BOD is doing it’s job.

There is one thing that has been on my mind for the past year of strange behaviour and failure at RVX but I’ve avoided mentioning because it is sensitive and personal but now I’ll mention it. A couple of posters have mentioned that Don has been spending a lot of his time in Hawaii. It was only a year ago that Don lost his soul mate to cancer. I sincerely hope that he is recovering from this loss. Then we had the YouTube with Don looking unshaven and in pajamas. We had the Saudi and African affairs. And now we are still seeing the company hide behind Covid as an excuse to limit shareholders attendance at the AGM. All of this adds up to making me very suspicious. I’m wondering if Don is still functioning from a business perspective? Is he doing anything to move the business ahead financially? I’ve never met Don so I may be way off base. I wish he’d talk to us and clarify the situation. It is his choice to clear the air.

On the science side we’ve seen the bungling of the Covid 2 trial but then we see the Ph3 USA trials with an exemplary steering committee. That reassures me.

On the business side we’ve just seen Eversana dial up the heat. Good news. In hindsight Don should have brought in a company like Versant first to provide funding for the trials…the numerous trials that should be underway. Get the cart behind the horse.

I really hope that Don does not try to pull off one of his “really excited about” presentations at the AGM. It will kill the SP.

We need to hear about concrete financing, partnerships and action plans that will be achieved even before the AGM.

Biotech is an extremely competitive and intense industry that requires high levels of education and expertise in science and business skills. RVX must deal with the weakness on the business side, specifically the financing component.

GLTA. Still long and hoping.   :(

Toinv